INTRODUCTION
Maintaining proper cellular proteostasis is essential for all life. Unfolded or misfolded proteins are susceptible to aggregation and can assemble into amyloid fibers. Highly ordered, b-sheetrich amyloid fibers are 8-10 nm wide and can be assembled by a variety of both native and intrinsically disordered proteins (Shewmaker et al., 2011; Eichner and Radford, 2011) . The distinct biochemical properties of all amyloids, resistance to protease digestion and chemical denaturants, and tinctorial properties when incubated with the dyes Congo red (CR) and thioflavin T (ThT) make identification and characterization of amyloids straightforward (Nilsson, 2004) . Amyloid deposits are one of the pathological hallmarks of neurodegenerative diseases, including Alzheimer's, Parkinson's, Huntington's, and Prion diseases (Chiti and Dobson, 2006) . Amyloid formation, however, is not always the result of protein misfolding. ''Functional'' amyloids are assembled by dedicated biogenesis systems, and amyloid polymers participate in various cellular functions ranging from mediating epigenetic inheritance, to sequestering toxins, to acting as structural components of biofilms (DePas and Chapman, 2012; Blanco et al., 2012) . Curli are an extracellular functional amyloid produced by enteric bacteria that aid in surface attachment and biofilm formation (Olsé n et al., 1989; Chapman et al., 2002; Pawar et al., 2005; Dueholm et al., 2012; DePas and Chapman, 2012; Hufnagel et al., 2013) . Curli biogenesis is exquisitely controlled so that curli amyloid fibers are only assembled at the right time and in place (Evans and Chapman, 2014; Mika and Hengge, 2013) .
The csg (curli-specific gene) operons encode the major structural and accessory proteins that are required for curli production (Hammar et al., 1995) . CsgD is a transcription factor that positively regulates the csgBAC operon (Zogaj et al., 2003; Dudin et al., 2014) . The csgBAC operon encodes the major and minor curli fiber components, CsgA and CsgB, respectively (Hammar et al., 1995) . CsgA is secreted to the extracellular milieu as an unfolded protein and then forms amyloid polymers upon interacting with the CsgB nucleator (Hammar et al., 1996 , Hammer et al., 2007 . Although CsgA amyloid formation in vivo is dependent on CsgB, CsgA can self-assemble into amyloid fibers in the absence of CsgB in vitro (Wang et al., 2007) . The csgDEFG operon encodes accessory and secretion proteins. CsgG assembles into a nonameric outer membrane pore that is required for secretion of CsgA and CsgB (Loferer et al., 1997; Goyal et al., 2014) . CsgE and CsgF are chaperone-like accessory proteins (Nenninger et al., 2009 (Nenninger et al., , 2011 . CsgE is a small periplasmic protein that is required for directing CsgA to CsgG for secretion, and CsgE can inhibit amyloid assembly of CsgA in vitro (Nenninger et al., 2011; Andersson et al., 2013) . CsgF is a surfaceexposed protein that associates with both CsgG and CsgB to tether the curli fiber to the cell surface (Nenninger et al., 2009 ). The csgBAC operon also encodes CsgC, a small b-sheet-rich periplasmic protein (Hammar et al., 1995; Gibson et al., 2007; Salgado et al., 2011; Taylor et al., 2011) . The role of CsgC during curli biogenesis has only been indirectly assessed and remains unknown (Gibson et al., 2007; Taylor et al., 2011) .
CsgA is secreted from the cell in an amyloid-competent, yet unpolymerized, form in vivo (Chapman et al., 2002; Gibson et al., 2007) . Mutations to csgG that prevent secretion do not result in the accumulation of intracellular CsgA or CsgB, although csgA and csgB are still expressed (Loferer et al., 1997) . This suggests that periplasmic CsgA and CsgB are somehow eliminated thereby preventing intracellular amyloid formation. We therefore sought to identify periplasmic chaperones and/or proteases that may be involved in ridding the cell of mislocalized curli subunits. We have previously identified two general cytoplasmic chaperones, DnaK and Hsp33, and one general periplasmic chaperone, Spy, that can inhibit CsgA amyloid assembly in vitro (Evans et al., 2011) . Furthermore, we found that CsgE can inhibit CsgA amyloid formation in vitro (Nenninger et al., 2011; Andersson et al., 2013) . These findings implicate an important role for molecular chaperones in inhibiting premature CsgA amyloid assembly during transport within the cell. Here we report that CsgC inhibits CsgA amyloid formation at substoichiometric concentrations and in the absence of a hydrolysable energy source. Further, we show that this bacterial protein inhibits human a-synuclein from forming amyloid fibers in vitro, while having no effect on human Ab 42 amyloid formation. Together, our results demonstrate that CsgC is both a highly efficient and selective inhibitor of amyloid formation.
RESULTS

Secretion-Deficient Mutants Have Periplasmic Amyloid Inhibitory Activity
CsgA is secreted across the outer membrane as a predominately unstructured protein (Gibson et al., 2007; Wang et al., 2007) . Furthermore, CsgA is undetectable in the secretion-deficient DcsgG mutant (Loferer et al., 1997) . We therefore hypothesized that efficient proteostatic mediators exist within the periplasm that prevent CsgA from prematurely forming amyloid aggregates inside the cell. To identify amyloid inhibitory factors we analyzed periplasmic extracts (PEs) from WT and curli (csg) mutant strains for the ability to prevent purified CsgA from aggregating into an amyloid in vitro. The csg mutant strains were grown under curli-inducing conditions prior to harvesting crude PEs by osmotic shock (modified from Quan et al., 2013) . PEs were normalized by total protein and added to 20 mM purified, SDS-soluble CsgA. CsgA polymerization into amyloid was then monitored by ThT fluorescence for 24 hr as previously described (Wang et al., 2007) . When purified CsgA was incubated alone, ThT fluorescence rapidly increased after approximately 2 hr of incubation indicative of CsgA amyloid assembly ( Figures 1A and 1B , closed squares). The addition of PEs from a DcsgG mutant to purified CsgA inhibited ThT fluorescence ( Figure 1A , open symbols). The inhibitory effect of the DcsgG PE was titratable: the addition of 100 mg/ml periplasmic protein to CsgA prevented ThT fluorescence for the duration of the experiment ( Figure 1A , open squares), while the addition of 25 mg/ml periplasmic proteins only delayed ThT fluorescence for approximately 8 hr ( Figure 1A , open triangles). In contrast, PEs from a complete curli deletion (Dcsg, deletion of both curli operons and the intergenic region) or PEs from a DcsgD mutant had little to no effect on ThT fluorescence of CsgA ( Figures 1B and S1A , open triangles). We previously found that CsgE is important for CsgA secretion, and that CsgE can inhibit CsgA amyloid formation in vitro (Nenninger et al., 2011; Andersson et al., 2013) . To test whether the observed inhibitory activity in the DcsgG PEs was due to CsgE, we deleted csgE in the DcsgG mutant background. We found that the DcsgGDcsgE and DcsgE PEs both strongly inhibited CsgA ThT fluorescence, demonstrating that CsgE was not responsible for the observed inhibitory activity ( Figure S1B ).
Inhibition of ThT fluorescence in the CsgA aggregation assay could be due to amyloid inhibition, proteolytic degradation of CsgA, or the direct inhibition of ThT fluorescence. To distinguish between these possibilities, the stability of CsgA was assessed in the presence and absence of DcsgD (not inhibitory; or Dcsg, data not shown) or DcsgG (inhibitory) PEs. After 24 hr the samples were separated into soluble and insoluble fractions by centrifugation and then analyzed by SDS-PAGE and western blot with or without HFIP treatment to solubilize CsgA amyloid aggregates ( Figure 1C ). When incubated alone or in the presence of the DcsgD PE, CsgA was found predominantly in the pelleted, SDS-insoluble fraction ( Figure 1C , lanes 4 and 8). In contrast, CsgA was still detected in the SDS-soluble fractions after incubation with the inhibitory DcsgG PE ( Figure 1C , lanes 9 and 10). Therefore, inhibition of ThT fluorescence by the DcsgG PE was the result of CsgA amyloid inhibition, and not proteolytic degradation of CsgA or quenching of ThT fluorescence.
CsgD Regulates Amyloid Inhibitory Activity
The observation that the DcsgD PE did not exhibit an amyloid inhibitory activity suggested that CsgD may regulate expression of the factor responsible for the activity. We therefore complemented the DcsgD mutant by expressing csgD from a plasmid. Expression of csgD was able to restore amyloid inhibitory activity to the DcsgD PEs (Figures 2A and S2A ). CsgD positively regulates the csgBAC operon, which encodes the known major and minor curli subunits, CsgA and CsgB, respectively (Hammar et al., 1995; Chapman et al., 2002) , as well as CsgC, whose function is poorly understood (Gibson et al., 2007; Taylor et al., 2011) . To determine if the amyloid inhibition activity was dependent on csgA, csgB, or csgC, PEs from various csg mutants were tested for inhibition of CsgA amyloid formation in vitro. We found that PEs from DcsgA or DcsgB mutants inhibited CsgA amyloid formation ( Figures 2B and S2B ). However, deletion of csgC alone or in the DcsgA or DcsgBDcsgA mutant backgrounds resulted in PEs that had less inhibitory activity ( Figure 2B ). Furthermore, PEs from a DcsgGDcsgC double mutant did not inhibit CsgA amyloid formation compared to PEs from a DcsgG single mutant ( Figure 2C ). Additionally, when size exclusion chromatography was used to fractionate the inhibitory DcsgG PEs further, western blot analysis revealed that CsgC was present in fractions that retained amyloid inhibitory behavior ( Figures S2C and  S2D ). Together, our genetic and biochemical analysis suggested that CsgC was responsible for the amyloid inhibition activity.
Cells Lacking CsgG and CsgC Accumulate Intracellular CsgA Subunits that go off pathway or are unable to be secreted might be prone to forming amyloid-like aggregates. We hypothesized that CsgC could discourage CsgA aggregation in the periplasm.
On CR-indicator plates, curliated cells stain red, while curli mutants produce white colonies (Hammar et al., 1995) . The DcsgG mutant forms white colonies on CR-indicator plates because CsgA and CsgB are not secreted to the cell surface, and no curli are assembled (Figures 3A, 3B, and S3B) (Loferer et al., 1997) . Interestingly, a DcsgGDcsgC double mutant produced pink colonies ( Figure 3A ) and could be restored to white by expressing csgC from a plasmid ( Figure 3A ). We then harvested the cells from YESCA plates and subjected them to western and dot blot analysis. Western blot analysis revealed that the DcsgGDcsgC mutant accumulated SDS-soluble and -insoluble CsgA (Figure 3B) . CsgA was no longer detected in the DcsgGDcsgC mutant when csgC was complemented on a plasmid ( Figure 3B ). Furthermore, CsgA produced by the DcsgGDcsgC mutant was only detected by dot blot western after cells were lysed (Figure 3C) , suggesting that the CsgA aggregates were intracellular. Similarly to the DcsgG mutant, and in contrast to WT and DcsgC mutant, no extracellular fibrillar aggregates were observed by TEM on the DcsgGDcsgC mutant ( Figures S3A-S3D ). Therefore, in the absence of CsgC, secretion-deficient mutants accumulate intracellular CsgA aggregates.
CsgC Protects the Cell from the Toxicity Associated with Intracellular CsgA Accumulation Amyloid aggregation can be toxic to biological membranes (Kayed et al., 2003 (Kayed et al., , 2004 . We therefore asked whether the accumulation of intracellular CsgA impacted the cellular fitness of the DcsgGDcsgC mutant. LIVE/DEAD staining with SYTO 9 and propidium iodide was used to assess the proportion of viable cells grown in curli-inducing conditions. We found that the DcsgGDcsgC colonies had a larger percentage of dead cells (13.4%) compared to the WT colonies (5.8%) ( Figure S3E ). We also asked whether the Cpx stress response was induced in the DcsgGDcsgC mutant. A cpxP promoter lacZ fusion was used to investigate induction of the Cpx response. There was 2-fold increase in Cpx induction in the DcsgGDcsgC cells at 48 hr compared to the WT ( Figure S3F ).
We also asked whether CsgC could protect against toxicity in the cytoplasm. When recombinant CsgA (CsgA 22-151 that lacks the SEC secretion signal sequence) was overexpressed, the growth of the culture was inhibited ( Figure S3G ). Interestingly, we found that coexpression of CsgA 22-151 with CsgC 9-110 (SEC minus) in the cytoplasm of BL21(DE3) cells significantly improved growth ( Figure S3G , closed circles). Cells coexpressing CsgA and CsgC in the cytoplasm continued to divide, reaching stationary phase and remaining viable after overnight incubation ( Figure S3G , closed circles). Expression of CsgC in the periplasm did not rescue the CsgA 22-151 -induced growth arrest ( Figure S3G , open circles). Collectively, these results demonstrated that CsgC prevented CsgA from forming toxic intracellular aggregates.
CsgC Inhibits Amyloid Formation
Our genetic and in vivo analyses suggested that CsgC has antiamyloid activity. Therefore, we purified recombinant CsgC and tested its ability to prevent CsgA polymerization in vitro. We found that purified CsgC inhibited CsgA amyloid formation at molar ratios as low as 1:500 (CsgC:CsgA) in vitro as measured by ThT fluorescence ( Figure 4A ). The same molar ratio of BSA:CsgA had little effect on CsgA polymerization ( Figure S4A ).
We were unable to observe CsgA fiber disassembly by CsgC over 24 hr (data not shown). We used another fluorescent dye, 8-anilino-1-naphthalenesulfonic acid (ANS) to test whether CsgC was directing CsgA into non-amyloid aggregates that did not bind ThT. Interestingly, CsgC also inhibited ANS fluorescence of CsgA, suggesting that CsgC does not simply direct CsgA into non-amyloid aggregates ( Figure S4C ). After 24 hr of incubation with CsgC, CsgA ran as an SDS-soluble protein on an SDS-PAGE gel ( Figure S4B) ; therefore, the inability of CsgA to adopt the SDS-resistant amyloid form in the presence of CsgC was again due to chaperone-like inhibition, and not due to proteolytic degradation ( Figure S4B ).
We then asked whether CsgC prevented CsgA from adopting the b-sheet-rich structure common to all amyloids (Tycko and Wickner, 2013) . CsgA transitions from an unstructured protein to a b-sheet-rich amyloid fiber as measured by far-UV circular dichroism (CD) (Wang et al., 2007; Horvath et al., 2012) . As seen in previous studies, CsgA was unstructured immediately after purification and by 24 hr adopted a largely b-sheet-secondary structure ( Figure 4B , closed symbols). However, when substoichiometric amounts of CsgC (1:10) were added to freshly purified CsgA, the CD spectrum of CsgA remained mostly unchanged for 24 hr ( Figure 4B , open symbols). CsgC is itself a b-sheet-rich protein ( Figure S4D) ; therefore, the minimal b sheet contribution from CsgC was subtracted from the CsgA+CsgC reaction. Even at 48 hr of incubation in the presence of CsgC, CsgA remained unfolded and non-amyloidogenic as measured by CD and ThT ( Figures S4E-S4G ).
To better understand how CsgC affects the structural transitions of CsgA over time, the 1 H NMR spectrum of CsgA alone or CsgA with CsgC was collected. Immediately after purification the 1 H NMR spectrum of CsgA alone showed the limited peak dispersion indicative of a disordered protein ( Figure 4C ). Over several hours the overall peak intensity gradually decreased as CsgA monomers became incorporated into aggregates and were lost from the NMR spectrum due to fast transverse relaxation ( Figure 4C ) (Horvath et al., 2012) . After approximately 10 hr the CsgA 1 H NMR spectrum had essentially disappeared, which coincided with maximal fluorescence in the ThT assay ( Figures  4A and 4C ). When CsgC was mixed with freshly purified CsgA at a molar ratio of 1:150, the 1 H NMR peaks of CsgA remained visible for over 24 hr ( Figure 4D ). In the presence of CsgC the CsgA 1 H NMR peaks decreased at a similar rate to the CsgAalone peaks during the first 3 hr, but then were relatively stable between 3 and 24 hr ( Figure 4E ). Given the low molar ratio of CsgC:CsgA required to achieve amyloid inhibition, we hypothesized that CsgC may be acting on multimeric species of CsgA. CsgA polymerization can be accelerated in vitro by the addition of either sonicated CsgA or CsgB preformed fibers in a process called ''seeding'' ( Figure 4F ) (Hammer et al., 2007; Wang et al., 2007; Zhou et al., 2012) . To address the question of whether CsgC inhibits fiber elongation we asked whether CsgC could inhibit amyloid assembly of CsgA in the presence of exogenously added CsgA seeds in vitro. The addition of 2% CsgA seeds by weight to freshly purified CsgA resulted in accelerated CsgA polymerization (Figure 4F, open versus closed squares) , while the addition of CsgC to CsgA at a 1:10 or 1:100 molar ratio inhibited CsgA polymerization ( Figure 4F , closed circles and triangles, respectively). Interestingly, the addition of seeds to CsgA in the presence of a 1:10 molar ratio of CsgC:CsgA was unable to overcome CsgC-mediated amyloid inhibition ( Figure 4F , circles). CsgA seeding was still largely inhibited even in the presence of CsgC at a 1:100 molar ratio of CsgC:CsgA ( Figure 4F, triangles) . We also asked if CsgC prolonged the transient, pre-amyloid state of CsgA that is recognized by the conformational-specific A11 antibody (Kayed et al., 2003) . The A11 antibody recognized CsgA incubated in the absence of CsgC immediately after purification, but not after 24 hr ( Figure 4G ) (Wang et al., 2007) . In contrast, the A11 antibody still recognized CsgA after 24 hr of incubation with CsgC ( Figure 4G ). Together, these results suggest that CsgC acts by stabilizing an A11-reactive pre-amyloid intermediate of CsgA.
To determine whether CsgC forms a stable complex with CsgA we analyzed CsgA in the absence and presence of CsgC by native gel electrophoresis. Freshly purified CsgA ran as several discrete bands approximately 66 kDa and smaller, suggesting that CsgA begins to self-associate rapidly after purification ( Figure 4H , lanes 1 and 2). CsgA that had been incubated at 25 C for 24 hr no longer migrated into the gel ( Figure 4H , lane 3). However, CsgA that had been incubated for 24 hr with a 3-fold substoichiometric concentration of CsgC had a similar banding pattern as CsgA immediately after purification ( Figure 4H , lane 5). The migration of CsgA and CsgC proteins in native gels suggested (1) that CsgC stabilizes CsgA in a heterogeneous mixture of homo-oligomeric species, and (2) that CsgA and CsgC do not form a stable hetero complex.
Next, we sought to identify the domain(s) of CsgA through which CsgC acts. CsgA is comprised of five imperfect repeating units (R1-R5). R1, R3, and R5 are amyloidogenic, while R2 and R4 contain gatekeeper residues that temper amyloid formation (Wang et al., 2007 (Wang et al., , 2010 . Deletion of R1, R3, or R5 in CsgA does not significantly abrogate CsgA amyloid assembly, and synthetic peptides corresponding to each of the amyloidogenic repeating units can self-assemble into amyloid fibers (Wang et al., 2007 . We therefore tested the ability of CsgC to inhibit amyloid assembly of the CsgA DR1, DR3, and DR5 mutants in vitro. We found that CsgC was still capable of inhibiting amyloid formation of each CsgA repeating unit deletion mutants at substoichiometric molar ratios ( Figures S5A-S5C ). We also found that CsgC inhibited amyloid assembly of synthetic peptides corresponding to CsgA R1 and R5 at substoichiometric concentrations ( Figures S5D and S5E) . Together, our results suggest that CsgC can interact with multiple domains of CsgA to inhibit amyloid assembly.
CsgC Displays Client Protein Selectivity
Finally, we next sought to explore the specificity of CsgC-mediated amyloid inhibition. Salmonella enterica and Citrobacter koseri both produce curli, and CsgA from both bacteria share approximately 75% sequence identity with E. coli CsgA . E. coli CsgA can be cross-seeded in vitro and in vivo by S. enterica and C. koseri CsgA . We found that E. coli CsgC was capable of inhibiting amyloid formation of CsgA molecules from S. enterica, C. koseri, and E. coli at the same molar ratios (Figures 5A and S5F) . The minor curli subunit, CsgB, shares 30% sequence identity with CsgA and can also assemble into an amyloid-like aggregate in vitro (Hammer et al., 2007 (Hammer et al., , 2012 . Furthermore, CsgB can seed CsgA polymerization both in vivo and in vitro (Hammer et al., 2007 (Hammer et al., , 2012 Wang et al., 2008) . We tested a truncated version of CsgB (CsgB trunc , lacking the fifth repeating unit) as a client for CsgC in vitro. We found that although CsgA and CsgB trunc share a large degree of similarity, a higher molar ratio (1:10, CsgC:CsgB trunc ) was required to achieve CsgB amyloid inhibition ( Figure 5B) .
We then asked if CsgC could act as a general amyloid inhibitor and inhibit human amyloid-forming proteins. The Alzheimer's disease-associated amyloid protein Ab 42 and the Parkinson's disease-associated protein a-synuclein were tested as potential CsgC clients. Even at a 1:1 molar ratio (CsgC:Ab 42 ), CsgC did not inhibit Ab 42 amyloid assembly ( Figure 5C ). In contrast, CsgC inhibited a-synuclein amyloid formation at 1:3 and 1:10 ratios and, to a lesser degree, at a 1:100 molar ratio ( Figure 5D ). Sequence alignments revealed a shared region in CsgA (residues 104-112: D-Q-W-N-G-K-N-E; corresponding to the loop region between R3 and R4) and in a-synuclein (residues 98-104: Figure 5F ). CsgC was able to inhibit amyloid formation by CsgA lacking residues 88-110 and synthetic peptides corresponding to the N-and C-terminal repeats of CsgA that contain similarly spaced glutamine and asparagine residues ( Figure S5) . However, the D-Q-F-X 0,1 -G-K-N-z-E motif only exists once in a-synuclein ( Figure 5F ). We mutated residues 98-104 in a-synuclein either to alanine residues (a-synuclein 6ala ) or a scrambled sequence (a-synuclein scram ) and asked whether CsgC could still inhibit amyloid assembly. Interestingly, CsgC only modestly affected the polymerization of a-synuclein variants that were missing the D-Q-F-X 0,1 -G-K-N-z-E motif ( Figures  5E and S5G) . Together, these results suggest a common CsgC interaction motif in CsgA and a-synuclein.
DISCUSSION
Protein misfolding and amyloid aggregation are hallmarks of many degenerative human diseases (Chiti and Dobson, 2006) . Modulating the protein folding environment as a means to ameliorate amyloid-associated diseases is an area of intense research focus (Balch et al., 2008; Lindquist and Kelly, 2011; Ryno et al., 2013) . Molecular chaperones have been shown to be important for inhibiting disease-associated amyloid assembly and amyloid-related cytotoxicity in vitro and in vivo (Broadley and Hartl, 2009 ). The heat shock protein Hsp70 inhibits amyloid assembly of the Alzheimer's disease-associated protein Ab and the Parkinson's disease-associated protein a-synuclein in vitro (Evans et al., 2006; Luk et al., 2008; Pemberton et al., 2011) . Overexpression of Hsp70 has also been found to reduce disease pathology in a murine model of Alzheimer's disease (Hoshino et al., 2011) . Similarly, overexpression of the small heat shock protein Hsp16.2 in a Caenorhabditis elegans model of Alzheimer's diseases resulted in decreased amyloid deposits and toxicity (Fonte et al., 2008) .
Functional amyloids, while sharing all of the biophysical characteristics of disease-associated amyloids, are distinguished from disease-associated amyloids by their dedicated and controlled biogenesis . Curli functional amyloid biogenesis is highly coordinated to ensure that curli fibers are assembled exclusively on the bacterial cell surface (Evans and Chapman, 2014) . Secretion of soluble curli subunits is, in part, facilitated by specific secretion (CsgE and CsgG) and nucleation (CsgB and CsgF) factors as well as general cytoplasmic and periplasmic molecular chaperones (Chapman et al., 2002; Evans et al., 2011; Hammar et al., 1996; Hammer et al., 2007 Hammer et al., , 2012 Nenninger et al., 2009 Nenninger et al., , 2011 Goyal et al., 2014) . We therefore asked whether the curli biogenesis system also encoded specific molecular inhibitors of intracellular CsgA amyloidogenesis.
Mislocalized curli subunits in the periplasm are unstable and degraded when outer membrane secretion is disrupted (Loferer et al., 1997) . We therefore hypothesized that periplasmic proteostatic mediators existed to efficiently inhibit mislocalized, intracellular CsgA from aggregating. Our in vitro analysis of PEs from curli mutants revealed an amyloid inhibitory activity in the periplasm of several mutant strains with curli gene deletions (Figures 1, 2 , S1, and S2). The addition of WT PEs accelerated or seeded CsgA polymerization in vitro likely due to extracellular curli fibers that copurified with the crude PEs (Figure S1A ; data not shown). Expression of csgD was required for the observed amyloid inhibitory activity (Figure 2A ). Further genetic analysis revealed that expression of csgC was required for CsgA amyloid inhibition in all of our inhibitory PEs (Figures 1, 2 , S1, and S2).
We found that CsgC could also inhibit intracellular CsgA amyloid assembly. Deletion of csgC in the DcsgG background results in the accumulation of intracellular CsgA aggregates ( Figures 3B  and 3C ). The CsgA trapped in these intracellular aggregates migrated on an SDS-PAGE gel with a size consistent with that of processed CsgA (lacking the SEC secretion signal sequence), suggesting that the CsgA aggregates were in the periplasm. CsgC does not appear to possess proteolytic activity itself ( Figures 1C and S4B) . It is likely that the CsgC maintains CsgA in a state that is competent for secretion or in a state that is sensitive to periplasmic proteases. In addition to CsgC, there may be other periplasmic proteins that can also discourage CsgA amyloid formation. Compared to a DcsgG mutant, PEs from a DcsgGDcsgC mutant exhibited greatly reduced amyloid inhibitory activity; however, the DcsgGDcsgC PEs still slightly impaired CsgA polymerization ( Figure 2C) . Interestingly, the Cpx stress response system, which positively regulates periplasmic chaperones and proteases, is induced approximately 2-fold in the DcsgGDcsgC mutant compared to WT ( Figure S3F ) (Danese et al., 1995; Raivio and Silhavy, 2001 ). The weak inhibitory activity of the DcsgGDcsgC PEs may therefore be due to an increased abundance of Cpx regulated periplasmic chaperones, which include Spy, a chaperone-like protein that has previously been shown to inhibit CsgA amyloid formation (Evans et al., 2011; Quan et al., 2011; Raffa and Raivio, 2002) .
When grown under curli-inducing conditions the DcsgG DcsgC mutant formed mucoid colonies, while WT, DcsgG, or DcsgC were non-mucoid (data not shown). Additionally, the DcsgGDcsgC cells clumped together when scraped off the agar surface and required vigorous vortexing to resuspend (data not shown). As amyloid intermediates can be toxic to membranes (Kayed et al., 2003 (Kayed et al., , 2004 , we hypothesized that the increased viscosity of the DcsgGDcsgC colonies was due to an increase in cell death. Indeed, the DcsgGDcsgC mutant had an increased number of dead cells per colony relative to the WT ( Figure S3E ). Although the growth defect of the DcsgGDcsgC mutant was only modest, this was not unexpected. There are two distinct cell populations within curli-dependent biofilms: one encased in a protective matrix of curli fibers and another that is not (DePas et al., 2013; Serra et al., 2013) . Furthermore, only about 30% of the cells in a biofilm express and assemble curli fibers (Epstein et al., 2009) . It is therefore likely that Cpx induction occurs in a subpopulation of curli-expressing cells, and only when secretion across the outer membrane fails. Furthermore, Cpx induction likely helps protect the cells by both downregulating the curli operons and upregulating periplasmic proteases and chaperones (Jubelin et al., 2005; Raivio and Silhavy, 2001 ). When we expressed a truncated allele of CsgA that remained in the cytoplasm we were able to induce growth arrest that was apparently linked to CsgA aggregation ( Figure S3G ). The CsgA-induced growth arrest was ameliorated when CsgC was coexpressed along with CsgA in the cytoplasm ( Figure S3G ).
CsgA amyloid formation can be inhibited by both protein and chemical ''chaperones'' acting via distinct mechanisms (Cegelski et al., 2009; Evans et al., 2011; Nenninger et al., 2011; Horvath et al., 2012; Andersson et al., 2013) . Protein chaperones that inhibit CsgA polymerization at molar ratios close to 1:1, such as Spy and CsgE, likely exert their inhibitory activity during early stages of aggregation by interacting with monomers of CsgA (Evans et al., 2011; Nenninger et al., 2011) . DnaK and Hsp33, on the other hand, inhibit CsgA polymerization at substoichiometric concentrations by interacting with early oligomers or inhibiting fiber elongation, respectively (Evans et al., 2011) . Small, heteroycyclic 2-pyridones designed as peptidomimetic compounds can inhibit CsgA amyloid assembly by diverting CsgA into ''off-pathway'' oligomers that are unable to assemble or nucleate amyloid formation (Horvath et al., 2012) . CsgC is a unique inhibitor of CsgA amyloid formation because it discourages CsgA amyloid formation at much lower molar ratios (1:500) than any other previously reported inhibitor (Figure 4A) (Cegelski et al., 2009; Nenninger et al., 2011; Evans et al., 2011; Andersson et al., 2013) . Biophysical and biochemical evidence (CD, NMR, ThT, seeding analysis, conformationspecific antibody analysis, gel electrophoresis) demonstrates that CsgC prevents CsgA from adopting the b-sheet-rich, SDS-insoluble, fibrous polymers (Figures 4 and S4) . In the presence of CsgC, CsgA remains in an unstructured conformation ( Figures 4B and S4D-S4F ), which can be distinguished from the off-pathway oligomers formed when CsgA is incubated with amyloid-inhibiting 2-pyridones (Horvath et al., 2012) . The potency of CsgC inhibition at substoichiometric concentrations suggests that it does not form stable 1:1 complexes with individual CsgA monomers to block amyloid formation. Instead it appears that CsgC acts somewhere further along the pre-amyloid folding pathway to stabilize an A11-reactive, non-amyloid species and inhibit transition into a fibrillar species . It is possible that CsgC binds dynamically to a soluble, but oligomeric, pool of CsgA, and prevents its escape from this ''molten oligomer'' to form seeds for nucleation into an amyloid ( Figure 6 ). Alternatively, CsgC may induce a structural change within a subpopulation of CsgA, which biases the whole population away from forming amyloid. Both explanations are consistent with our data. Unlike previously reported general molecular chaperones that can inhibit CsgA amyloid formation, CsgC appears to have client protein selectivity (Figures 5 and S5A ) (Evans et al., 2011) . E. coli CsgC inhibited the aggregation of CsgA proteins from closely related bacterial species, C. koseri and S. enterica, each of which shares 75% sequence identity with E. coli CsgA (Figures 5A and  S5F) . Furthermore, CsgC inhibited a truncation mutant of the E. coli minor curli subunit CsgB from assembling into an amyloid ( Figure 5B ). Although CsgB is closely related to CsgA, sharing 30% sequence identity with CsgA and b-sheet-rich secondary structure, a higher molar ratio of CsgC:CsgB was required to achieve amyloid inhibition over 24 hr ( Figure 5B ). This implies that while CsgC is able to recognize CsgB at some stage during amyloidogenesis, the sites where CsgB differs from CsgA allow it to escape the action of CsgC more easily.
CsgC also inhibited amyloid formation of the human Parkinson's disease-associated protein a-synuclein, but not the Alzheimer's disease-associated protein Ab 42 ( Figures 5C and  5D ). Although Ab 42 does not share recognizable sequence homology with CsgA, an alignment of a-synuclein with CsgA revealed a shared D-Q-F-X 0,1 -G-K-N-z-E motif that maps to R3 of CsgA and residues 98-104 of a-synuclein ( Figure 5B ). The D-Q-F-X 0,1 -G-K-N-z-E motif is less well conserved in CsgB (Figure 5F ). Remarkably, mutagenesis of residues 98-104 of a-synuclein to alanine residues (6ala) reduced the ability of CsgC to inhibit a-synuclein amyloid assembly ( Figures 5E and 5F ). a-synuclein contains three domains: an N-terminal amphipathic domain, a hydrophobic ''non-amyloid component of Alzheimer's disease'' (NAC), and a C-terminal domain sometimes referred to as the solubilizing domain ( Figure S5A ) (Bartels et al., 2010; Giasson et al., 2001; Murray et al., 2003; Serpell et al., 2000) . Interestingly, the D-Q-F-X 0,1 -G-K-N-z-E motif shared with CsgA R3 maps to the C-terminal/solubilizing domain of a-synuclein suggesting that CsgC may be modulating the solubilizing activity of the a-synuclein C-terminal domain. The presence of the D-Q-F-X 0,1 -G-K-N-z-E motif in a-synuclein is important for CsgC-mediated amyloid inhibition; however, it appears that CsgA possesses multiple domains through which CsgC can mediate amyloid inhibition ( Figure 5 ). CsgA is comprised of five imperfect repeating units that have distinct propensities to form amyloid. R1, R3, and R5 are highly amyloidogenic, while R2 and R4 are not (Wang et al., 2007 . R2 and R4 contain specific ''gatekeeper'' residues that temper amyloid formation and that are not present in repeating units R1, R3, or R5 (Wang et al., 2010) . We found that CsgC can inhibit amyloid assembly of CsgA R1, R3, and R5 deletion mutants as well as synthetic peptides corresponding to R1 and R5 (Figures S5A-S5E) . CsgB is similarly comprised of five imperfect repeating units with R1, R2, and R4 being the most amyloidogenic (Hammer et al., 2012) . While the exact sequence motif in CsgA R3 that is shared with a-synuclein is not found in the other repeating units of CsgA or CsgB, a second similar motif, Q-X-G-X 1,2 -N-X 5 -Q, can be found in all the CsgA and CsgB repeating units as well as in a-synuclein ( Figure S5H ). The observation that there may be multiple CsgC recognition domains in CsgA explains why CsgC was able to inhibit the polymerization of CsgA R1, R3, and R5 deletion mutants in addition to synthetic peptides corresponding to R1 and R5 ( Figures S5A-S5E) . Collectively, these data suggest that CsgC client protein selectivity is dictated by a short, 8-to 10-amino-acid sequence that is repeated several times in CsgA and CsgB, but only once in a-synuclein ( Figures  5E and S5A ).
Specific amyloid inhibition by proteins at substoichiometric concentrations is not unprecedented. Grafted amyloid motif antibodies (gammabodies) have been engineered to contain amyloid domains of various amyloid-forming proteins. Gammabodies specifically recognize the amyloid conformation of the target protein and can in some instances inhibit amyloid formation of the target protein at a 10-fold substoichiometric concentration Perchiacca et al., 2012) . In another report, the monomeric form of transthyretin (M-TTR) has been shown to inhibit Ab and HypF-N amyloid oligomer toxicity in vitro at molar ratios comparable to those of CsgC and CsgA (1:100-1:500) (Cascella et al., 2013) . Although not completely understood, the gammabody-client protein-protien interactions that prevent amyloid formation are hypothesized to be mediated through intermolecular amyloid-like contacts Perchiacca et al., 2012) . CsgC is non-amyloidogenic under all of the conditions that we have tested, but it is a b-sheet-rich protein that might mimic the amyloid form of CsgA, leaving open the possibility that CsgC interacts with CsgA via an amyloid-like interaction. Clarifying how these amyloid inhibitors interact with their client amyloid-forming proteins awaits high-resolution biophysical studies.
EXPERIMENTAL PROCEDURES
See Supplemental Information.
PE Preparation
Overnight cultures were plated as a lawn on a YESCA plate and grown for 48 hr at 26 C. Cells were scraped off the plate with 3 ml of 20 mM Tris (pH 8.0).
OD 600 nm 40 units for each strain were harvested by centrifugation at 8,000 3 g, resuspended in 500 ml of osmotic shock buffer (30 mM Tris [pH 7.2], 40% sucrose, 2 mM EDTA), and incubated at room temperature for 10 min. Cells were pelleted for 10 min at 16,000 3 g, resuspended in 500 ml of cold 2 mM MgCl 2 , incubated on ice for 3 min, and pelleted at 16,000 3 g for 10 min at 4 C. The supernatant was kept as the periplasmic fraction. All experiments were performed in BW25113 and MC4100 backgrounds at least three times and yielded very similar results.
Amyloid Inhibition Assays
Monomeric CsgA, CsgADR1, CsgADR3, CsgADR5, CsgBDR5, Ab 42 , or a-synuclein were added to 10 ml of 50 mM KPi (pH 7.3), 100 mM NaCl, or CsgC in a black flat-bottom 96-well plate with 20 mM ThT. The samples were incubated either in a Molecular Devices SpectraMax M2 or a Tecan Infinite M200 microtiter plate reader at 25 C. The plate was shaken linearly for 3 s prior to taking fluorescence readings (excitation, 438 nm; emission, 495 nm; cutoff, 475 nm) every 10 or 20 min. a-synuclein polymerization assays were conducted at 37 C with constant agitation with a 2 nm glass bead in each well. Seeding experiments were conducted by adding 2% (by weight) CsgA fibers that had been sonicated with a probe sonicator 3 3 10 sec to each reaction. Graphs are representative of at least three independent experiments. Values are reported as normalized ThT fluorescence; buffer or CsgC-alone values were subtracted from sample values and were divided by the maximum ThT reading for each sample and smoothed in KaleidaGraph (Synergy Software).
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental Experimental Procedures and can be found with this article online at http://dx.doi. org/10.1016/j.molcel.2014.12.025.
